Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.73 |
| ▸ | MEN1 | O00255 | 5/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | MAPT | P10636 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 5/20 | 0.61 |
| ▸ | PABPC1 | P11940 | 4/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19151059 | 0.86 | KMT2A (0.75) | KMT2AMEN1KDM4EMAPTLMNA | |
| SCHEMBL10509419 | 0.84 | KMT2A (1.00) | KMT2AMEN1KDM4EMAPTLMNA | |
| SCHEMBL19002813 | 0.83 | MEN1 (0.71) | KMT2AMEN1KDM4EMAPTLMNA | |
| SCHEMBL22560791 | 0.83 | KMT2A (0.71) | KMT2AMEN1KDM4EMAPTLMNA | |
| SCHEMBL19116804 | 0.83 | KMT2A (0.71) | KMT2AMEN1KDM4EMAPTLMNA | |
| SCHEMBL23975890 | 0.83 | KMT2A (0.71) | KMT2AMEN1KDM4EMAPTLMNA | |
| Hydrochloric Acid SCHEMBL10511823 | 0.83 | KMT2A (0.97) | KMT2AMEN1KDM4EMAPTLMNA | |
| Hydrochloric Acid SCHEMBL5652109 | 0.82 | KMT2A (0.69) | KMT2AMEN1KDM4EMAPTLMNA | |
| Hydrochloric Acid SCHEMBL30225159 | 0.82 | KMT2A (0.69) | KMT2AMEN1KDM4EMAPTLMNA | |
| SCHEMBL13263619 | 0.81 | MEN1 (0.68) | KMT2AMEN1KDM4EMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092747-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BENDER STEVEN LEE (US) | 2004-05-13 | — | — | US | disclosed |
| US-6635641-B2 | For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis | AGOURON PHARMACEUTICALS, INC. | 2003-10-21 | — | — | US | disclosed |
| EP-1252146-A1 | AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20020103203-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2001053274-A1 | AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092747-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BRAF, CNKSR1, UACA | KMT2A 3246/4885MEN1 4396/4885KDM4E 1227/4885 |
| US-20020103203-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BRAF, CNKSR1, UACA | KMT2A 3246/4885MEN1 4396/4885KDM4E 1227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.